SEC Form 4 · accession 0001127602-18-015443
LEXICON PHARMACEUTICALS, INC. · LXRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Raymond Debbane
Director
Period of report
Apr 27, 2018
Accepted (ET)
Apr 27, 2018 · 5:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001062822
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 27, 2018 | A | 2,564 | $0.00 | A | 12,902 | D | |
| Common Stock | holding | — | — | — | 4,321,214 | I | By Invus C.V. |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $7.80 | Apr 27, 2018 | A | 2,857 | A | — | Apr 27, 2028 | Common Stock | 2,857 | 2,857 | D |
Explanation of responses
- F1Option vests with respect to 1/12th of the shares subject to the option for each month of service following the date of grant.